RT Journal Article
SR Electronic
T1 Positive Airway Pressure Therapy Predicts Lower Mortality and Major Adverse Cardiovascular Events Incidence in Medicare Beneficiaries with Obstructive Sleep Apnea
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.26.23293156
DO 10.1101/2023.07.26.23293156
A1 Mazzotti, Diego R
A1 Waitman, Lemuel R.
A1 Miller, Jennifer
A1 Sundar, Krishna M.
A1 Stewart, Nancy H.
A1 Gozal, David
A1 Song, Xing
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/02/15/2023.07.26.23293156.abstract
AB Background Obesity is associated with obstructive sleep apnea (OSA) and cardiovascular risk. Positive airway pressure (PAP) is the first line treatment for OSA, but evidence on its beneficial effect on major adverse cardiovascular events (MACE) prevention is limited. Using claims data, the effects of PAP on mortality and incidence of MACE among Medicare beneficiaries with OSA were examined.Methods A cohort of Medicare beneficiaries with ≥2 distinct OSA claims was defined from multi-state, state-wide, multi-year (2011-2020) Medicare fee-for-service claims data. Evidence of PAP initiation and utilization was based on PAP claims after OSA diagnosis. MACE was defined as a composite of myocardial infarction, heart failure, stroke, or coronary revascularization. Doubly robust Cox proportional hazards models with inverse probability of treatment weights estimated treatment effects controlling for sociodemographic and clinical factors.Results Among 888,835 beneficiaries with OSA (median age 73 years; 43.9% women; median follow-up 1,141 days), those with evidence of PAP initiation (32.6%) had significantly lower all-cause mortality (HR [95%CI]: 0.53 [0.52-0.54]) and MACE incidence risk (0.90 [0.89-0.91]). Higher quartiles of annual PAP claims were progressively associated with lower mortality (Q2: 0.84 [0.81-0.87], Q3: 0.76 [0.74-0.79], Q4: 0.74 [0.72-0.77]) and MACE incidence risk (Q2: 0.92 [0.89-0.95], Q3: 0.89 [0.86-0.91], Q4: 0.87 [0.85-0.90]).Conclusion PAP utilization was associated with lower all-cause mortality and MACE incidence among Medicare beneficiaries with OSA. Results might inform trials assessing the importance of OSA therapy towards minimizing cardiovascular risk and mortality in older adults.Competing Interest StatementDr. Krishna Sundar was a past advisory board member for Resmed Inc. and is the co-founder of Hypnoscure LLC through the University of Utah Technology Commercialization Office All other authors declared no conflicts of interest.Funding StatementThe study was funded by the American Heart Association (20CDA35310360), Patient-Centered Outcomes Research Institute (RI-CRN-2020-003-IC); NIH CTSA NCATS Frontiers: University of Kansas Clinical and Translational Science Institute (UL1TR002366); Tier 2 grant, University of Missouri.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the Institutional Review Board of the University of Missouri-Columbia on behalf of each participating institution of the Greater Plains Collaborative (Allina Health, Indiana University, Intermountain Healthcare, Marshfield Clinic, Medical College of Wisconsin, University of Iowa, University of Kansas Medical Center, University of Nebraska Medical Center, University of Texas Health Sciences Center at San Antonio, University of Texas Southwestern, University of Utah, Washington University in St. Louis) and determined to be minimal risk and therefore approved the waiver of authorization under the Privacy Rule. 45 CFR 164.512 (i)(1)(i)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesATEaverage treatment effectCCICharlson comorbidity indexCIconfidence intervalCMSCenters for Medicare & Medicaid ServicesCOPDchronic obstructive pulmonary diseaseCPAPcontinuous positive airway pressureCVcardiovascularDMEdurable medical equipmentHFheart failureHRhazards ratioMACEmajor adverse cardiovascular eventsMImyocardial infarctionOSAobstructive sleep apneaPAPpositive airway pressurePSpropensity scoresRCTrandomized controlled trials.